Clozapine ameliorates epigenetic and behavioral abnormalities induced by phencyclidine through activation of dopamine D1 receptor

Yuki Aoyama, Akihiro Mouri, Kazuya Toriumi, Takenao Koseki, Shiho Narusawa, Natsumi Ikawa, Takayoshi Mamiya, Taku Nagai, Kiyofumi Yamada, Toshitaka Nabeshima

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Abstract Accumulating evidence suggests that dysregulation of histone modification is involved in the pathogenesis and/or pathophysiology of psychiatric disorders. However, the abnormalities in histone modification in the animal model of schizophrenia and the efficacy of antipsychotics for such abnormalities remain unclear. Here, we investigated the involvement of histone modification in phencyclidine-induced behavioral abnormalities and the effects of antipsychotics on these abnormalities. After repeated phencyclidine (10 mg/kg) treatment for 14 consecutive days, mice were treated with antipsychotics (clozapine or haloperidol) or the histone deacetylase inhibitor sodium butyrate for 7 d. Repeated phencyclidine treatments induced memory impairment and social deficit in the mice. The acetylation of histone H3 at lysine 9 residues decreased in the prefrontal cortex with phencyclidine treatment, whereas the expression level of histone deacetylase 5 increased. In addition, the phosphorylation of Ca2+/calmodulin-dependent protein kinase II in the nucleus decreased in the prefrontal cortex of phencyclidine-treated mice. These behavioral and epigenetic changes in phencyclidine-treated mice were attenuated by clozapine and sodium butyrate but not by haloperidol. The dopamine D1 receptor antagonist SCH-23390 blocked the ameliorating effects of clozapine but not of sodium butyrate. Furthermore, clozapine and sodium butyrate attenuated the decrease in expression level of GABAergic system-related genes in the prefrontal cortex of phencyclidine-treated mice. These findings suggest that the antipsychotic effect of clozapine develops, at least in part, through epigenetic modification by activation of the dopamine D1 receptor in the prefrontal cortex.

Original languageEnglish
Pages (from-to)723-737
Number of pages15
JournalInternational Journal of Neuropsychopharmacology
Volume17
Issue number5
DOIs
Publication statusPublished - 05-2014

Fingerprint

Phencyclidine
Dopamine D1 Receptors
Clozapine
Epigenomics
Butyric Acid
Histone Code
Prefrontal Cortex
Antipsychotic Agents
Haloperidol
Calcium-Calmodulin-Dependent Protein Kinase Type 2
Histone Deacetylase Inhibitors
Histone Deacetylases
Dopamine Antagonists
Acetylation
Histones
Lysine
Psychiatry
Schizophrenia
Animal Models
Phosphorylation

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology
  • Psychiatry and Mental health
  • Medicine(all)

Cite this

Aoyama, Yuki ; Mouri, Akihiro ; Toriumi, Kazuya ; Koseki, Takenao ; Narusawa, Shiho ; Ikawa, Natsumi ; Mamiya, Takayoshi ; Nagai, Taku ; Yamada, Kiyofumi ; Nabeshima, Toshitaka. / Clozapine ameliorates epigenetic and behavioral abnormalities induced by phencyclidine through activation of dopamine D1 receptor. In: International Journal of Neuropsychopharmacology. 2014 ; Vol. 17, No. 5. pp. 723-737.
@article{d40a689740744533bf0d7d1ad6593c12,
title = "Clozapine ameliorates epigenetic and behavioral abnormalities induced by phencyclidine through activation of dopamine D1 receptor",
abstract = "Abstract Accumulating evidence suggests that dysregulation of histone modification is involved in the pathogenesis and/or pathophysiology of psychiatric disorders. However, the abnormalities in histone modification in the animal model of schizophrenia and the efficacy of antipsychotics for such abnormalities remain unclear. Here, we investigated the involvement of histone modification in phencyclidine-induced behavioral abnormalities and the effects of antipsychotics on these abnormalities. After repeated phencyclidine (10 mg/kg) treatment for 14 consecutive days, mice were treated with antipsychotics (clozapine or haloperidol) or the histone deacetylase inhibitor sodium butyrate for 7 d. Repeated phencyclidine treatments induced memory impairment and social deficit in the mice. The acetylation of histone H3 at lysine 9 residues decreased in the prefrontal cortex with phencyclidine treatment, whereas the expression level of histone deacetylase 5 increased. In addition, the phosphorylation of Ca2+/calmodulin-dependent protein kinase II in the nucleus decreased in the prefrontal cortex of phencyclidine-treated mice. These behavioral and epigenetic changes in phencyclidine-treated mice were attenuated by clozapine and sodium butyrate but not by haloperidol. The dopamine D1 receptor antagonist SCH-23390 blocked the ameliorating effects of clozapine but not of sodium butyrate. Furthermore, clozapine and sodium butyrate attenuated the decrease in expression level of GABAergic system-related genes in the prefrontal cortex of phencyclidine-treated mice. These findings suggest that the antipsychotic effect of clozapine develops, at least in part, through epigenetic modification by activation of the dopamine D1 receptor in the prefrontal cortex.",
author = "Yuki Aoyama and Akihiro Mouri and Kazuya Toriumi and Takenao Koseki and Shiho Narusawa and Natsumi Ikawa and Takayoshi Mamiya and Taku Nagai and Kiyofumi Yamada and Toshitaka Nabeshima",
year = "2014",
month = "5",
doi = "10.1017/S1461145713001466",
language = "English",
volume = "17",
pages = "723--737",
journal = "International Journal of Neuropsychopharmacology",
issn = "1461-1457",
publisher = "Cambridge University Press",
number = "5",

}

Clozapine ameliorates epigenetic and behavioral abnormalities induced by phencyclidine through activation of dopamine D1 receptor. / Aoyama, Yuki; Mouri, Akihiro; Toriumi, Kazuya; Koseki, Takenao; Narusawa, Shiho; Ikawa, Natsumi; Mamiya, Takayoshi; Nagai, Taku; Yamada, Kiyofumi; Nabeshima, Toshitaka.

In: International Journal of Neuropsychopharmacology, Vol. 17, No. 5, 05.2014, p. 723-737.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clozapine ameliorates epigenetic and behavioral abnormalities induced by phencyclidine through activation of dopamine D1 receptor

AU - Aoyama, Yuki

AU - Mouri, Akihiro

AU - Toriumi, Kazuya

AU - Koseki, Takenao

AU - Narusawa, Shiho

AU - Ikawa, Natsumi

AU - Mamiya, Takayoshi

AU - Nagai, Taku

AU - Yamada, Kiyofumi

AU - Nabeshima, Toshitaka

PY - 2014/5

Y1 - 2014/5

N2 - Abstract Accumulating evidence suggests that dysregulation of histone modification is involved in the pathogenesis and/or pathophysiology of psychiatric disorders. However, the abnormalities in histone modification in the animal model of schizophrenia and the efficacy of antipsychotics for such abnormalities remain unclear. Here, we investigated the involvement of histone modification in phencyclidine-induced behavioral abnormalities and the effects of antipsychotics on these abnormalities. After repeated phencyclidine (10 mg/kg) treatment for 14 consecutive days, mice were treated with antipsychotics (clozapine or haloperidol) or the histone deacetylase inhibitor sodium butyrate for 7 d. Repeated phencyclidine treatments induced memory impairment and social deficit in the mice. The acetylation of histone H3 at lysine 9 residues decreased in the prefrontal cortex with phencyclidine treatment, whereas the expression level of histone deacetylase 5 increased. In addition, the phosphorylation of Ca2+/calmodulin-dependent protein kinase II in the nucleus decreased in the prefrontal cortex of phencyclidine-treated mice. These behavioral and epigenetic changes in phencyclidine-treated mice were attenuated by clozapine and sodium butyrate but not by haloperidol. The dopamine D1 receptor antagonist SCH-23390 blocked the ameliorating effects of clozapine but not of sodium butyrate. Furthermore, clozapine and sodium butyrate attenuated the decrease in expression level of GABAergic system-related genes in the prefrontal cortex of phencyclidine-treated mice. These findings suggest that the antipsychotic effect of clozapine develops, at least in part, through epigenetic modification by activation of the dopamine D1 receptor in the prefrontal cortex.

AB - Abstract Accumulating evidence suggests that dysregulation of histone modification is involved in the pathogenesis and/or pathophysiology of psychiatric disorders. However, the abnormalities in histone modification in the animal model of schizophrenia and the efficacy of antipsychotics for such abnormalities remain unclear. Here, we investigated the involvement of histone modification in phencyclidine-induced behavioral abnormalities and the effects of antipsychotics on these abnormalities. After repeated phencyclidine (10 mg/kg) treatment for 14 consecutive days, mice were treated with antipsychotics (clozapine or haloperidol) or the histone deacetylase inhibitor sodium butyrate for 7 d. Repeated phencyclidine treatments induced memory impairment and social deficit in the mice. The acetylation of histone H3 at lysine 9 residues decreased in the prefrontal cortex with phencyclidine treatment, whereas the expression level of histone deacetylase 5 increased. In addition, the phosphorylation of Ca2+/calmodulin-dependent protein kinase II in the nucleus decreased in the prefrontal cortex of phencyclidine-treated mice. These behavioral and epigenetic changes in phencyclidine-treated mice were attenuated by clozapine and sodium butyrate but not by haloperidol. The dopamine D1 receptor antagonist SCH-23390 blocked the ameliorating effects of clozapine but not of sodium butyrate. Furthermore, clozapine and sodium butyrate attenuated the decrease in expression level of GABAergic system-related genes in the prefrontal cortex of phencyclidine-treated mice. These findings suggest that the antipsychotic effect of clozapine develops, at least in part, through epigenetic modification by activation of the dopamine D1 receptor in the prefrontal cortex.

UR - http://www.scopus.com/inward/record.url?scp=84898059120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898059120&partnerID=8YFLogxK

U2 - 10.1017/S1461145713001466

DO - 10.1017/S1461145713001466

M3 - Article

C2 - 24345457

AN - SCOPUS:84898059120

VL - 17

SP - 723

EP - 737

JO - International Journal of Neuropsychopharmacology

JF - International Journal of Neuropsychopharmacology

SN - 1461-1457

IS - 5

ER -